Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 DAS181 treatment of hematopoietic stem cell transplant patients with parainfluenza virus lung disease requiring mechanical ventilation.

Literature DB >> 24383501

DAS181 treatment of hematopoietic stem cell transplant patients with parainfluenza virus lung disease requiring mechanical ventilation.

S Chalkias¹, M R Mackenzie, C Gay, C Dooley, F M Marty, R B Moss, T Li, R L Routh, S R Walsh, C S Tan.

Abstract

Parainfluenza infection is a cause of significant morbidity and mortality in allogeneic hematopoietic stem cell transplant (HSCT) patients. DAS181 is a novel antiviral agent with activity against influenza and parainfluenza. We report the first 2 cases, to our knowledge, of successful DAS181 use in ventilated HSCT patients with severe parainfluenza lung disease.

Entities: Chemical Disease Gene Species

Keywords: DAS181; HSCT; mechanical ventilation; parainfluenza

Mesh：

Substances：

Year: 2014 PMID： 24383501 PMCID： PMC4469988 DOI： 10.1111/tid.12177

Source DB: PubMed Journal: Transpl Infect Dis ISSN： 1398-2273 Impact factor: 2.228

10 in total

1. A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo.

Authors: Anne Moscona; Matteo Porotto; Samantha Palmer; Caroline Tai; Lori Aschenbrenner; Gallen Triana-Baltzer; Qi-Xiang Li; David Wurtman; Stefan Niewiesk; Fang Fang
Journal: J Infect Dis Date: 2010-07-15 Impact factor: 5.226

Review 2. End points for testing influenza antiviral treatments for patients at high risk of severe and life-threatening disease.

Authors: Michael G Ison; Menno D de Jong; Kevin J Gilligan; Elizabeth S Higgs; Andrew T Pavia; Jerome Pierson; Frederick G Hayden
Journal: J Infect Dis Date: 2010-06-01 Impact factor: 5.226

3. Treatment of parainfluenza 3 infection with DAS181 in a patient after allogeneic stem cell transplantation.

Authors: Yi-Bin Chen; Jessica P Driscoll; Steven L McAfee; Thomas R Spitzer; Eric S Rosenberg; Rebecca Sanders; Ronald B Moss; Fang Fang; Francisco M Marty
Journal: Clin Infect Dis Date: 2011-08-31 Impact factor: 9.079

Review 4. Entry of parainfluenza virus into cells as a target for interrupting childhood respiratory disease.

Authors: Anne Moscona
Journal: J Clin Invest Date: 2005-07 Impact factor: 14.808

5. The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation.

Authors: Roy F Chemaly; Santosh S Hanmod; Dhanesh B Rathod; Shashank S Ghantoji; Ying Jiang; Arpan Doshi; Karen Vigil; Javier A Adachi; Andrew M Khoury; Jeffery Tarrand; Chitra Hosing; Richard Champlin
Journal: Blood Date: 2012-01-12 Impact factor: 22.113

6. Clinical potential of DAS181 for treatment of parainfluenza-3 infections in transplant recipients.

Authors: B B Guzmán-Suarez; M W Buckley; E T Gilmore; E Vocca; R Moss; F M Marty; R Sanders; L R Baden; D Wurtman; N C Issa; F Fang; S Koo
Journal: Transpl Infect Dis Date: 2012-02-16 Impact factor: 2.228

7. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome.

Authors: W G Nichols; L Corey; T Gooley; C Davis; M Boeckh
Journal: Blood Date: 2001-08-01 Impact factor: 22.113

8. A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection.

Authors: Ronald B Moss; Carrie Hansen; Rebecca L Sanders; Stephen Hawley; Tiejun Li; Roy T Steigbigel
Journal: J Infect Dis Date: 2012-10-08 Impact factor: 5.226

9. DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient.

Authors: D R Drozd; A P Limaye; R B Moss; R L Sanders; C Hansen; J D Edelman; G Raghu; M Boeckh; R M Rakita
Journal: Transpl Infect Dis Date: 2012-12-26 Impact factor: 2.228

Review 10. The use of sialidase therapy for respiratory viral infections.

Authors: John M Nicholls; Ronald B Moss; Stuart M Haslam
Journal: Antiviral Res Date: 2013-04-17 Impact factor: 5.970

10 in total

22 in total

Review 1. Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies.

Authors: Roy F Chemaly; Dimpy P Shah; Michael J Boeckh
Journal: Clin Infect Dis Date: 2014-11-15 Impact factor: 9.079

Review 2. Clinical pharmacokinetics of inhaled antimicrobials.

Authors: Chris Stockmann; Jessica K Roberts; Venkata K Yellepeddi; Catherine M T Sherwin
Journal: Clin Pharmacokinet Date: 2015-05 Impact factor: 6.447

3. Parainfluenza Virus 3-Specific T Cells: Opportunity for Intervention?

Authors: Alpana Waghmare; Janet A Englund; Michael Boeckh
Journal: J Infect Dis Date: 2017-07-15 Impact factor: 5.226

4. Phase 1 clinical trials of DAS181, an inhaled sialidase, in healthy adults.

Authors: Jonathan M Zenilman; Edward J Fuchs; Craig W Hendrix; Christine Radebaugh; Robert Jurao; Seema U Nayak; Robert G Hamilton; J McLeod Griffiss
Journal: Antiviral Res Date: 2015-09-25 Impact factor: 5.970

Review 5. How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation.

Authors: Alpana Waghmare; Janet A Englund; Michael Boeckh
Journal: Blood Date: 2016-03-11 Impact factor: 22.113